President Trump says after 1-1.5 years, Tariffs on Foreign Pharmaceutical’s are going to Skyrocket to 250%

“We want pharmaceutical’s to be made in America..” NOT CHINA!

🔴 For my investors out there…

I’ve been watching the Kodak stock since 2020, when President Trump put forth the Defense Production Act, and made an announcement about Kodak producing pharmaceuticals. The goal was to repurpose Kodak’s chemical manufacturing facilities in Rochester, New York.

• As of today, Kodak is now independently heavily investing tens of millions into a new lab and manufacturing facility at Eastman Business Park, New York, expected to open sometime this year.

• Fast forward to a few months ago, President Trump’s announced tariffs will target foreign pharmaceutical companies… and now we have a TIMELINE.

This positions Kodak to produce APIs and reagents DOMESTICALLY, placing them way ahead of the competition (which are coming too) by planning this restructuring since 2020, with its facility already nearing completion today, unlike competitors who may need years to relocate or build U.S.-based operations.

Kodak is a fantastic undervalued American company that I believe will be critical in the near future.

• Tariffs will likely raise costs for foreign-made APIs, making Kodak’s domestic production more competitive and potentially boosting demand… and its stock.

• Also, with potential short term drug shortages looming due to tariffs, Kodak’s soon established U.S.-based supply could see emergency demand spikes.

• Kodak’s stock historically surged (e.g., 300% in 2020 after the loan news).

*Disclaimer: this isn’t financial advice. This is my own research for educational purposes.